41 results
Page 2 of 3
8-K
EX-99.2
a7hdgbj9r56y u2s07q
24 Sep 19
Durability of Response Determined to be 89 Percent at Six Months and 84 Percent at 12 Months
5:20pm
10-Q
ysk2e6i51l7cb
9 May 19
Quarterly report
7:13am
DEF 14A
33d9san574wv6
26 Apr 19
Definitive proxy
5:00pm
10-K
5c4zi7htcm5gbta8
28 Feb 19
Annual report
1:08pm
10-K
EX-10.12
mwg6xxtirbi8433
28 Feb 19
Annual report
1:08pm
424B5
us7n8l0n8503p8led
25 Jan 19
Prospectus supplement for primary offering
8:01am
424B5
ovg k9lcb
22 Jan 19
Prospectus supplement for primary offering
5:12pm
8-K
EX-99.2
ifr99iz wv
22 Jan 19
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares
5:08pm
6-K
EX-99.2
tmvb 1gv6f
13 Nov 18
Current report (foreign)
6:33am
6-K
EX-99.2
fe6b67
14 Aug 18
Current report (foreign)
4:09pm
6-K
EX-99.2
uhd a0ewh
15 May 18
Current report (foreign)
4:24pm
20-F
xm8nd4f cfo9f
15 Mar 18
Annual report (foreign)
12:00am